Floatz logo

Jcar017 (Lisocabtagene Maraleucel)

Immune System Disorder

Juno Therapeutics, a Subsidiary of CelgeneCell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Immune System Disorder cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Indapta Therapeutics, INC.
Phase 2BB
Fludarabine
Indapta Therapeutics, INC.
Phase 2BB
LIDOCAINE
Ciusss de L'Est de l'Île de Montréal
Phase 4BB
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Washington University School of Medicine
Phase 2B
Zilovertamab
Oncternal Therapeutics, Inc
Phase 3B

View all 38 →

Same molecule, other indications

Jcar017 (Lisocabtagene Maraleucel) is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
non-Hodgkin lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →